05.17 2021
IBI302 is advancing to Phase II clinical trial by Innovent Biologics
The global development rights for IBI302 have been licensed to Innovent Biologics INC (1801.HK).
建議您使用以下瀏覽器觀看本網站，以獲得最佳瀏覽效果。
